Skip to main content

Absence of Venous Thromboembolism Risk Following Quadrivalent Human Papillomavirus Vaccination, Vaccine Safety Datalink, 2008–2011

    Basic Details
    Medical Product
    quadrivalent human papillomavirus vaccination (HPV4)
    Health Outcome(s)
    venous thromboembolism (VTE)

    To investigate concerns about a potential association between quadrivalent human papillomavirus vaccination (HPV4) and venous thromboembolism (VTE), a self-controlled case series study was conducted in adolescents and young adults 9–26 years of age in the Vaccine Safety Datalink.


    Allison L. Naleway PhD, Brad Crane, Ning Smith, Matthew F. Daley MD, James Donahue, Julianne Gee Sharon K. Greene PhD, MPH, Theresa Harrington, Lisa A. Jackson MD, MPH, Nicola P. Klein MD, PhD, Hung Fu Tseng, Claudia Vellozzi MD, Eric S. Weintraub


    Corresponding Author

    Allison L. Naleway, Center for Health Research, Kaiser Permanente Northwest, 3800 N. Interstate Ave., Portland, OR 97227; T: 1.503 335 6352; E: